/PRNewswire/ The "Global Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Industry Trends Analysis Report By Application (C.difficile,.
AcuraBio selects Cytiva's latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene therapies The latest purification technology will offer efficient processing time for plasmid DNA production BRISBANE, Australia, Feb. 10, 2023 /PRNewswire/ AcuraBio, a leading Australian biopharmaceutical contract development and manufacturing organization (CDMO), will provide a cGMP plasmid DNA CDMO service to the world using Cytiva's new process platform technology. Jon Ince (left), General Manager, Australia & New Zealand, Cytiva and Guillaume Herry (right), CEO of AcuraBio, at the contract signing ceremony AcuraBio expects to produce more plasmid DNA for its customers around the world using Cytiva's latest bacterial plasmid two-step purification protocol. The new protocol features single-use purification technology which delivers efficiency, high purity level outcome and s
AcuraBio selects Cytiva's latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene therapiesThe